Related Experiment Video
Updated: Aug 5, 2025
06:07
Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells
Published on: June 13, 2020
6.7K
Free Fatty Acids from Cow Urine DMSO Fraction Induce Cell Death in Breast Cancer Cells without Affecting Normal GMSCs
Ajay Kumar Raj1, Vidhi Upadhyay1, Kiran Bharat Lokhande2
1Cancer and Translational Research Lab, Dr. D. Y. Patil Biotechnology & Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune 411033, Maharashtra, India.
Biomedicines
|March 29, 2023
Summary
Free fatty acids (FFAs) from cow urine DMSO fraction (CUDF) show antiproliferative effects against breast cancer cells. These FFAs, including tetracosanedioic acid, may inhibit histone deacetylase (HDAC), explaining their anti-cancer activity.
Area of Science:
- Biochemistry
- Cancer Biology
- Natural Products Chemistry
Background:
- Metabolic heterogeneity influences cancer cell plasticity and drug response.
- Free fatty acid (FFA) availability is linked to tumor heterogeneity.
Purpose of the Study:
- To investigate the biological relevance of FFAs from cow urine DMSO fraction (CUDF).
- To evaluate the in vitro and in silico anti-cancer potential of CUDF.
Main Methods:
- CUDF was prepared from cow urine and tested for anti-cancer effects on breast cancer cell lines (MCF-7, ZR-75-1).
- Intracellular metabolites were analyzed using vertical tube gel electrophoresis (VTGE).
- Molecular docking and dynamics simulations were used to study FFA interactions with histone deacetylase (HDAC).
Main Results:
- CUDF significantly reduced breast cancer cell viability and induced cell death.
- Specific FFAs, including tetracosanedioic acid, were identified within treated MCF-7 cells.
- Identified FFAs demonstrated affinity for HDAC inhibitory sites, comparable to known inhibitors.
Conclusions:
- FFAs from CUDF exhibit potential as antiproliferative and pro-apoptotic agents against breast cancer.
- Tetracosanedioic acid and other FFAs may act as HDAC inhibitors, contributing to observed anti-cancer effects.
